Is Regeneron Pharmaceuticals (REGN) Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?

Why It Matters

The clearance opens a new therapeutic market for Regeneron and showcases its gene‑therapy platform, potentially boosting investor confidence and future pipeline value.

Key Takeaways

• FDA greenlights Otarmeni, first gene therapy for genetic deafness
• Treatment targets OTOF gene, helping 20‑50 newborns annually
• Otarmeni will be provided free under FDA priority voucher program
• Regeneron’s portfolio already includes Dupixent, Eylea, and other blockbusters
• Steve Cohen lists Regeneron among top biotech investment picks

Pulse Analysis

Gene therapy has moved from experimental labs to mainstream approvals, and Regeneron’s Otarmeni marks a watershed moment for auditory disorders. The treatment delivers a functional copy of the OTOF gene via an adeno‑associated viral vector directly into the cochlea, restoring the missing otoferlin protein that enables sound transduction. While the condition—otoferlin‑related hearing loss—affects only 20 to 50 newborns in the United States each year, its rarity underscores the technical hurdles that Regeneron has overcome. The approval signals that viral‑based delivery can be safely applied to delicate inner‑ear structures, opening doors for similar approaches to other sensory deficits.

The FDA’s priority review voucher attached to Otarmeni adds a strategic financial layer. S. patients. This model reduces the commercial risk for Regeneron while still delivering tangible value through voucher monetization. Competitors such as Eli Lilly are already testing parallel gene‑editing strategies, suggesting a nascent race to dominate the rare‑disease hearing market.

Early clinical signals of efficacy could accelerate additional indications and broaden the company’s rare‑disease portfolio. From an investment standpoint, the approval bolsters Regeneron’s reputation as a leader in precision medicine, complementing its blockbuster assets like Dupixent and Eylea. Billionaire investor Steve Cohen’s endorsement of Regeneron as a top biotech pick reflects confidence in its pipeline depth and cash‑flow generation. While some analysts argue that AI‑focused stocks may offer higher short‑term upside, Regeneron’s diversified revenue base and proven ability to bring complex biologics to market provide a more balanced risk‑return profile for long‑term investors.